Date: 2016-11-15
Type of information: Research agreement
Compound: Orbital® Inhaler with a dry powder formulation of tobramycin
Company: Pharmaxis (Australia) Woolcock Institute of Medical Research (Australia)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: research - R&D
Action mechanism:
Disease: cystic fibrosis
Details: • On November 15, 2016, Pharmaxis announced a research collaboration with Sydney’s prestigious Woolcock Institute of Medical Research to develop a novel inhalation therapy, Orbital inhaler, for the treatment of cystic fibrosis. The Orbital inhaler is a Pharmaxis invention which has been designed to deliver high?doses of dry powder drugs to the lungs in a more effective and convenient manner than existing technology. The project will be led by Woolcock Institute Deputy Director and Head of Respiratory Technology Professor Paul Young along with Professors Daniela Traini and Scott Bell. A Phase 1 clinical trial conducted by Pharmaxis has shown the Orbital can administer large amounts of dry powder to healthy subjects in one inhalation without compromising safety or tolerability. The compact device is capable of housing up to 400mg of powder for inhalation within a specially designed dosing chamber and delivers sequential doses to the patient with a simple one touch deployment. Pharmaxis has previously developed Bronchitol® an inhaled dry powder for the treatment of cystic fibrosis. The product is approved and marketed in Europe, Russia and Australia and a third large multicentre clinical trial is currently underway aiming to secure approval in the United States.
Financial terms: The National Health and Medical Research Council (NHMRC) has awarded a research grant of $421,545 for development and testing of the Orbital® Inhaler with a dry powder formulation of the antibiotic tobramycin.
Latest news:
